# IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

> **NCT07377643** · PHASE3 · RECRUITING · sponsor: **Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.** · enrollment: 540 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** IBI354
- **DRUG:** Docetaxel
- **DRUG:** Pertuzumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT07377643
- **Lead sponsor:** Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-10
- **Primary completion:** 2028-04-28
- **Final completion:** 2030-05-31
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07377643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07377643, "IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-14 from https://api.ai-analytics.org/clinical/NCT07377643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*